newsfilter
← Latest News
PR Newswire·

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced...